Examkin

Question

Difficulty: MediumImmunologic and Inflammatory Processes

A 45-year-old man is hospitalized for the treatment of relapsed diffuse large B-cell lymphoma. Three days ago, he received an infusion of anti-CD19 chimeric antigen receptor (CAR) T cells. He now acutely develops a temperature of 39.8°C (103.6°F), a heart rate of 125/min, and blood pressure of 82/45 mm Hg that is unresponsive to a 2-liter intravenous fluid bolus. Oxygen saturation is 93% on room air. Laboratory evaluation reveals profoundly elevated serum ferritin, C-reactive protein, and lactate dehydrogenase. The patient is diagnosed with a severe immunologic complication related to his recent cellular therapy. Which of the following is the most appropriate targeted intervention for this patient's current condition?

  1. Administration of a monoclonal antibody that blocks the interleukin-6 receptorAnswer
  2. B
    Administration of a monoclonal antibody that directly neutralizes tumor necrosis factor-alpha
  3. C
    Administration of a monoclonal antibody targeting CD52 to deplete circulating lymphocytes
  4. D
    Immediate performance of a bone marrow aspiration and biopsy
  5. E
    Administration of a cytochrome P450 3A4 inhibitor to prolong the circulating half-life of the therapy

Answer

Administration of a monoclonal antibody that blocks the interleukin-6 receptor
This patient is experiencing severe Cytokine Release Syndrome (CRS), a life-threatening complication of chimeric antigen receptor (CAR) T-cell therapy. The profound activation of engineered CAR-T cells interacting with tumor antigens leads to downstream activation of bystander immune cells, particularly macrophages. This massive immune activation results in the release of large quantities of pro-inflammatory cytokines, with interleukin-6 (IL-6) being the primary driver of the systemic response. The clinical presentation classically includes high fever, distributive shock, and markedly elevated acute phase reactants such as ferritin and C-reactive protein. The most appropriate targeted therapy for hemodynamically unstable CRS is an IL-6 receptor antagonist, such as tocilizumab, often combined with systemic corticosteroids.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and recent therapeutic history.
The patient presents with high fever, refractory distributive shock, and markedly elevated inflammatory markers (ferritin, CRP) three days after receiving CAR-T cell therapy.
Establishing the clinical diagnosis of Cytokine Release Syndrome (CRS) is the required first step before selecting a targeted therapy.
2
Identify the primary immunopathologic mechanism driving the clinical condition.
Severe CRS is driven by massive systemic immune activation, predominantly mediated by extreme elevations of the cytokine interleukin-6 (IL-6) secreted by macrophages.
Understanding the primary cytokine mediator is necessary to select the most precise targeted pharmacotherapy.
3
Select the specific targeted immunologic intervention.
An IL-6 receptor antagonist (such as tocilizumab) is the standard of care for severe, hemodynamically unstable CRS.
This agent directly neutralizes the pathophysiologic driver of the cytokine storm without destroying the therapeutic CAR-T cells.

Key Concept

Cytokine Release Syndrome (CRS) following CAR-T cell therapy is a systemic inflammatory response primarily mediated by interleukin-6 (IL-6) and is managed acutely with targeted IL-6 receptor antagonists.
Estimated Time:1m 30s
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic